Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

68.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,250
Open 68.62
Bid (Size) 68.72 (3)
Ask (Size) 69.25 (1)
Prev. Close 68.62
Today's Range 68.62 - 68.62
52wk Range 62.34 - 142.00
Shares Outstanding 400,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DEXCOM, INC. (NASDAQ: DXCM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds DexCom, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-44.25%
-44.25%
1 Month
-1.56%
-1.56%
3 Month
-38.16%
-38.16%
6 Month
-50.96%
-50.96%
1 Year
-17.41%
-17.41%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orthofix, Spire Global, DexCom, and Methode Electronics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today
Via Benzinga
What the Options Market Tells Us About DexCom
Via Benzinga
Is DexCom a Millionaire Maker?
Via The Motley Fool
2 Beaten-Down Growth Stocks You Might Regret Not Buying
Via The Motley Fool
Is DexCom a Millionaire Maker?
Via The Motley Fool
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom
From Faruqi & Faruqi LLP
Via GlobeNewswire
Down More Than 50%, Is DexCom Stock a Bargain Now?
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orthofix, Spire Global, DexCom, and Methode Electronics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
From The Rosen Law Firm PA
Via GlobeNewswire
DEXCOM, INC. (NASDAQ: DXCM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds DexCom, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
2 Magnificent Growth Stocks Down 45% and 32% to Buy Right Now
Via The Motley Fool
DXCM DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before October 21, 2024
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
DXCM DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before October 21, 2024
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LONGSTANDING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orthofix, Spire Global, DexCom, and Arbor Realty and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Notifies Investors of Lead Plaintiff Deadline in Dexcom Inc. (DXCM) Securities Class Action
From Kirby McInerney LLP
Via GlobeNewswire
DexCom Inc. October 21, 2024 Lead Plaintiff Deadline – DXCM Investors Should Contact Robbins LLP for Information
From Robbins LLP
Via GlobeNewswire
Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom
From Faruqi & Faruqi LLP
Via GlobeNewswire
DexCom Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against DexCom, Inc. (DXCM) – Deadline is October 21, 2024
From Kaplan Fox & Kilsheimer LLP
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.